Did Orasure Technologies beat or miss consensus estimates last quarter?

What were the key takeaways from Orasure Technologies’s earnings call?

What guidance did Orasure Technologies's management provide for the next earnings period?

What were the key takeaways from Orasure Technologies's earnings call?

What is Orasure Technologies's gross profit margin?

What is the revenue and EPS growth rate for Orasure Technologies year over year?

What is Orasure Technologies's latest dividend and current dividend yield?

What factors drove the changes in Orasure Technologies's revenue and profit?

- **Revenue Performance**: Q3 core revenue $27 million, with Diagnostics and Sample Management stable amid market challenges.
- **Strategic Acquisition**: BioMedomics adds Sickle SCAN, targeting underserved markets with potential for $1-3 million annual revenue growth.
- **Cost Efficiency**: Improved gross margin (43.5%) and disciplined OpEx, enabling $10 million Q4 innovation investment.
- **Pipeline Momentum**: Sherlock CT/NG submission expected in late 2025, alongside proteomics and STI product launches.
- **Financial Strength**: $216 million cash, no debt, and disciplined capital deployment.

**【CEO Summary Section】**
- **Q3 2025 Financials**: Total revenue of $27.1 million, with core revenue at $27.0 million. Diagnostics contributed $14.5 million, and Sample Management $10.3 million.
- **International Diagnostics**: Anticipated 20% revenue decline in 2025 due to inventory challenges, with BioMedomics acquisition adding Sickle SCAN for underserved markets.
- **U.S. Diagnostics**: Expansion into non-public health markets (e.g., urgent care, correctional facilities) and renewal of Together Take Me Home program, adding $1.8 million in Q4.
- **Sample Management**: Flat year-over-year revenue but poised for growth in 2026; collaboration with ENDO 1000 project for endometriosis research.
- **Innovation Pipeline**: Launch of HEMAcollect PROTEIN for proteomics, Colli-Pee for STI testing, and Sherlock CT/NG platform in late 2025/early 2026.

**【CFO Financial Commentary】**
- **Q3 Financials**: GAAP operating loss of $16.1 million, non-GAAP loss of $12.7 million. Gross margin 43.5% (44.2% non-GAAP), driven by lower scrap costs.
- **Balance Sheet**: $216 million cash, no debt. $5 million share repurchase and $10 million Q4 innovation investment (Sherlock platform).
- **Q4 Guidance**: Revenue $25-28 million, lower gross margin due to international mix.

**【Q&A Highlights】**
- **BioMedomics Acquisition**: $4 million upfront, potential contingent consideration. Expected to be cash flow breakeven with attractive ROI via OTI's existing channels.
- **Cost Management**: Lower scrap expenses and efficient OpEx allocation, with core business breakeven and innovation-focused spending.
- **In-Sourcing Impact**: No lingering costs; operational efficiencies maintained.


OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript

- **Revenue Resilience**: Core revenue of $30.8 million beat expectations, driven by Diagnostics growth and new product launches despite challenges in Sample Management.
- **Manufacturing Efficiency**: Transition to internal manufacturing will improve margins starting in 2026, with Q3 gross margin stable at 42.1%.
- **Innovation Momentum**: HEMAcollect PROTEIN and Colli-Pee are gaining early traction, with potential for significant growth in proteomics and self-collection diagnostics.
- **Strategic Adjustments**: Reduced reliance on the consumer genetics customer and cautious outlook for the Together Take Me Home program reflect management's focus on sustainable growth.

**【CEO Summary Section】**
- **Revenue Performance**: Q2 core revenue of $30.8 million exceeded the midpoint of guidance. Diagnostics grew 3% YoY, while Sample Management declined 22% YoY due to a large consumer genetics customer. Excluding this customer, core revenue growth would have been 5% YoY.
- **Strategic Initiatives**: Launched HEMAcollect PROTEIN for proteomics research and completed the transition of Sample Management manufacturing to internal capabilities in Pennsylvania, ahead of schedule.
- **Market Challenges**: International Diagnostics faced delays due to USAID funding freezes, but U.S. Diagnostics remained steady. The Together Take Me Home program may continue, though funding uncertainty impacts Q3 revenue expectations.
- **New Product Momentum**: HEMAcollect PROTEIN received positive customer feedback, and Colli-Pee urine collection device is on track for FDA submission in 2025. Sherlock's CT/NG test submission is expected by year-end.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP gross margin improved to 42.1%, and non-GAAP gross margin was 43.2%. Operating cash flow was negative $10 million due to innovation investments. Cash reserves stood at $235 million with no debt.
- **Q3 Guidance**: Revenue expected between $27 million and $30 million, reflecting lower contributions from the consumer genetics customer and reduced Together Take Me Home program revenue ($0.5 million vs. $2 million in Q2).
- **Cost Efficiency**: Transition to internal manufacturing will drive margin improvements starting in 2026, with benefits ramping up with volume.

**【Q&A Key Highlights】**
- **Manufacturing Transition**: Benefits of in-house manufacturing will materialize in 2026, with margin leverage dependent on volume. Q3 gross margin is expected to remain stable with Q2 levels.
- **Diagnostics Market Dynamics**: International orders slowed due to inventory digestion, but U.S. Diagnostics growth is being diversified into clinical settings. Together Take Me Home's future funding remains uncertain.
- **Product Traction**: HEMAcollect PROTEIN is gaining traction in proteomics research, with applications in oncology, neurology, and metabolic disorders. Colli-Pee and Sherlock's CT/NG test are positioned for long-term growth in self-collection diagnostics.

OraSure Technologies, Inc. (OSUR) Q2 2025 Earnings Call Transcript

- **Core Growth Drivers**: Diagnostics up 8% YoY on international expansion, offsetting SMS disruption. WHO-prequalified HCV test gains traction in Africa.
- **Critical Program Risk**: $4 million annual decline in U.S. HIV testing program highlights funding uncertainty.
- **Innovation Payoff**: Sherlock molecular platform on track for 2025 submission; microbiome kits target $100M+ women's health market.
- **Operational Strength**: $248M cash balance, 80% manufacturing in-sourcing complete, supporting 2025+ efficiency gains.
- **Shareholder Return**: $40M buyback to begin Q2, signaling confidence in long-term value.


**【CEO Key Highlights】**
- **Core Revenue Performance**: Q1 core revenue of $29.5 million exceeded midpoint of guidance, with Diagnostics up 8% YoY driven by international growth, offsetting SMS decline of 16% due to a disrupted consumer genomics customer.
- **International Diagnostics Resilience**: Despite U.S. funding uncertainty, international business remains stable, with WHO-prequalified HCV self-test gaining traction in Africa. U.S. public health programs face headwinds, including $4 million annual decline in Together Take Me Home program.
- **Innovation Momentum**: 
  - Sherlock Biosciences' low-cost molecular diagnostic platform advancing CT/NG clinical trial, targeting 2025 regulatory submission.
  - New microbiome extraction kits launching in June, targeting women's health and dermatology applications.
  - Colli-Pee urine collection device supporting Color Health's HPV test in all 50 U.S. states.
- **Manufacturing Efficiency**: In-sourcing SMS production to Bethlehem, PA, 80% complete by Q2, enabling cost savings and operational flexibility.

**【CFO Financial Summary】**
- **Q1 Financials**: Total revenue $29.9 million (GAAP), with core operating loss of $15.3 million (non-GAAP). Gross margin 41.7% (non-GAAP), stable vs. prior quarter.
- **Cash Position**: $248 million in cash, no debt. Q1 operating cash outflow $19.7 million due to innovation investments and seasonal working capital.
- **Q2 Guidance**: Core revenue $28-32 million, with $40 million stock buyback authorization over 2 years, to begin in Q2.

**【Q&A Key Takeaways】**
- **International Funding Trends**: Multilateral programs (e.g., Global Fund) show stability, while U.S.-funded programs face delays. Customer engagement suggests gradual resumption of activity.
- **Customer Risk Mitigation**: Diversified customer base reduces reliance on single accounts; 2025 renewals with Myriad Genetics and Fulgent Genetics highlight loyalty to OTI's saliva collection devices.
- **Sherlock Platform Progress**: $7-8 million quarterly investment in molecular diagnostics, with CT/NG test submission expected by year-end.
- **Tariff Impact**: Minimal exposure due to U.S./Canada supply chain; in-sourcing strategy limits trade policy risk.


OraSure (OSUR)-7 May 25-2025 Q1 Earnings call transcript

- **Core Growth Momentum**: Q4 core revenue up 10% YoY, driven by strong international Diagnostics and SMS segments.
- **Innovation Pipeline**: Sherlock acquisition positions for molecular diagnostics expansion; Sapphiros blood collection device on track for 2025 launch.
- **Margin Expansion**: 2025 adjusted gross margin target 50%, supported by automation and cost optimization initiatives.
- **External Risk Management**: Monitoring PEPFAR funding freeze and NIH cuts, with Q1 guidance reflecting near-term uncertainty.

**【CEO Strategic Update】**
- **Core Revenue Growth**: Q4 core revenue of $36.5M (+10% YoY), driven by Diagnostics (+9%) and Sample Management Solutions (+14%).
- **Strategic Acquisitions**: Acquired Sherlock Biosciences for molecular diagnostics platform; first test (CTNG) expected FDA submission by end-2025.
- **Regulatory Milestones**: FDA approval to expand OraQuick HIV self-test to 14+ age group; $7.5M BARDA contract for Marburg virus test development.
- **Operational Efficiency**: Positive cash flow from core business; $268M cash on hand with zero debt.

**【CFO Financial Highlights】**
- **Q4 Financials**: Total revenue $37.4M; core revenue $36.5M (+10% YoY). Non-GAAP gross margin 40.1%, below expectations due to mix and one-time costs.
- **2025 Guidance**: Core revenue $27-31M (Q1); adjusted gross margin target 50% by year-end. Operating expenses to remain disciplined amid external uncertainty.
- **Cost Optimization**: Automation, facility consolidation, and in-sourcing expected to drive 2025 margin expansion.

**【Q&A Key Takeaways】**
- **External Risks**: PEPFAR funding freeze impacting ~14% of intl. Diagnostics; NIH cuts affecting <10% of SMS revenue. Q1 guidance reflects these uncertainties.
- **Product Pipeline**: Sapphiros blood collection device on track for 2025 regulatory approval. Sherlock's molecular platform integration progressing.
- **BARDA Contract**: $7.5M initial funding; potential $11M total if milestones met. Leverages Ebola expertise for Marburg virus test development.

OSUR

OSUR fundamentals

Earnings Call

You can ask Aime